Moderna would seek limited emergency use of COVID-19 vaccine based on
early data
Send a link to a friend
[September 17, 2020]
By Julie Steenhuysen
CHICAGO (Reuters) - If Moderna Inc's
COVID-19 vaccine proves to be at least 70 percent effective, the company
plans to seek emergency authorization for its use in high-risk groups,
the company's chief executive told Reuters.
Moderna's vaccine candidate - mRNA-1273 - is nearing the finish line in
its push to enroll 30,000 individuals in a late-stage trial of a novel
coronavirus vaccine. But the company may be able to declare victory
early if it is able to show that people who got the vaccine fared much
better in its trial that people who didn't.
Vaccines must demonstrate they are at least 50% moreeffective than a
placebo to be considered for approval. To provethat, government
officials have said, at least 150 COVID-19infections must be recorded
among trial participants with atleast twice as many occurring among the
placebo group.
If a vaccine is especially effective, companies could havetheir answer
sooner.
![](http://archives.lincolndailynews.com/2020/Sep/17/images/ads/current/humanesociety_sda022411.png)
An independent safety board will take a first look at Moderna's data as
soon as a total of 53 people in the trial become infected with COVID-19.
Moderna is projecting the interim analysis will occur in November, but
it could come as early as October.
If most of the people who got sick got the placebo shot, that would
indicate the vaccine was protecting those inoculated and could be enough
evidence to seek U.S. regulatory approval for Emergency Use
Authorization(EUA).
"If the interim readout is deemed by the independent safety committee as
positive with 70 or 80 or 90% efficacy, we will indeed consider
approval," Stephane Bancel, Moderna's chief executive officer, said in a
telephone interview.
"At such a level of efficacy, if we get there, we can protect a lot of
lives in the people at the highest risk, and so, we will consider filing
for an EUA for a very limited population," Bancel said.
He said the FDA will determine whether the benefit of the vaccine to a
small group of high-risk individuals outweighs the risk of not having a
full readout of safety data from all 30,000 study participants.
The two groups of high-risk individuals who might be covered in such an
EUA would be healthcare workers and the elderly, Bancel said.
[to top of second column]
|
![](../images/091720PIX/news_m25.jpg)
A sign marks the headquarters of Moderna Therapeutics, which is
developing a vaccine against the coronavirus disease (COVID-19), in
Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian
Snyder/File Photo
![](../images/ads/current/fitzpatrick_lda_SPONSOR_2017.png)
Bancel said the company wants to gather more data on the safety of
the vaccine in the study population over a period of several months
before seeking full FDA approval.
Moderna released its study protocol on Thursday, making public
details on how its vaccine will be evaluated. If the vaccine does
not reach the efficacy mark after 53 cases, the data safety and
monitoring board will take another interim look at the data after
106 cases, and a final look after 151 people in the trial become
infected with the virus.
Public health officials have said that approving a vaccine for
widespread use based on a small number of cases would not offer
enough safety information to show how the vaccine would perform.
Moderna, which has never brought a vaccine to market, hasreceived
nearly $1 billion from the U.S. government under itsOperation Warp
Speed program. It has also struck a $1.5 billionsupply agreement
with the United States.
In a presentation to investors on Tuesday, Pfizer Inc said the
company has enrolled more than 29,000 people in its 44,000-volunteer
trial to test an experimental COVID-19 vaccine the company is
developing with German partner BioNTech.
![](http://archives.lincolndailynews.com/2020/Sep/17/images/ads/current/rohlfs_lda_072017.png)
Pfizer expects to have enough data to show whether the vaccine works
by the end of October.
(Reporting by Julie Steenhuysen; editing by Peter Henderson and
Cynthia Osterman)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |